Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) shareholders are probably feeling a little disappointed, since its shares fell 5.0% to US$19.96 in the week after its latest first-quarter results. Results look to have been somewhat negative - revenue fell 7.0% short of analyst estimates at US$65m, although statutory losses were somewhat better. The per-share loss was US$0.48, 21% smaller than the analysts were expecting prior to the result. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

Taking into account the latest results, the most recent consensus for Syndax Pharmaceuticals from twelve analysts is for revenues of US$346.4m in 2026. If met, it would imply a major 60% increase on its revenue over the past 12 months. The loss per share is expected to greatly reduce in the near future, narrowing 41% to US$1.63. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$358.5m and losses of US$1.65 per share in 2026.

There was no real change to the average price target of US$39.58, suggesting that the revisions to revenue estimates are not expected to have a long-term impact on Syndax Pharmaceuticals' valuation. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on Syndax Pharmaceuticals, with the most bullish analyst valuing it at US$57.00 and the most bearish at US$29.00 per share. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. It's clear from the latest estimates that Syndax Pharmaceuticals' rate of growth is expected to accelerate meaningfully, with the forecast 86% annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 22% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 21% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Syndax Pharmaceuticals is expected to grow much faster than its industry.

The Bottom Line

The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. They also downgraded Syndax Pharmaceuticals' revenue estimates, but industry data suggests that it is expected to grow faster than the wider industry. The consensus price target held steady at US$39.58, with the latest estimates not enough to have an impact on their price targets.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have forecasts for Syndax Pharmaceuticals going out to 2028, and you can see them free on our platform here.

Plus, you should also learn about the 1 warning sign we've spotted with Syndax Pharmaceuticals .

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.